Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

800-Patient study aims to uncover best treatments for kidney disease

NCT ID NCT06926244

First seen Jun 02, 2026 · Last updated Jun 22, 2026 · Updated 4 times

Summary

This observational study will follow 800 adults with IgA nephropathy, a common kidney disease, to see how well current treatments control protein in the urine and preserve kidney function over 12 months. Researchers want to understand why some patients do not respond to standard therapies. The study does not test a new drug but gathers real-world data to guide future treatment decisions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Nephrology department, Hospital Pitié - Salpêtrière (ASSISTANCE PUBLIQUE HOPITAUX DE PARIS AP-HP)

    RECRUITING

    Paris, 75013, France

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this study could identify which treatments work best in real-world settings for IgA nephropathy, helping doctors choose more effective therapies.

What could go wrong

This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by differences in patient care and adherence.

Conditions

The condition(s) this trial relates to.

IgA glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.